TY - JOUR
T1 - Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors
AU - Sella, Tal
AU - Zheng, Yue
AU - Rosenberg, Shoshana M.
AU - Ruddy, Kathryn J.
AU - Gelber, Shari I.
AU - Tamimi, Rulla M.
AU - Peppercorn, Jeffrey M.
AU - Schapira, Lidia
AU - Borges, Virginia F.
AU - Come, Steven E.
AU - Carey, Lisa A.
AU - Winer, Eric P.
AU - Partridge, Ann H.
N1 - Funding Information:
The Young Women’s Breast Cancer Study is funded by the Breast Cancer Research Foundation (A.H.P.) and Komen (A.H.P.). Tal Sella is supported by the Pinchas Borenstein Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Tel HaShomer, Israel. The authors would also like to thank Kate Bifolck and Valerie Hope Goldstein for their assistance with editing and manuscript submission. The study was previously presented as a spotlight poster at the 2021 San Antonio Breast Cancer Symposium, Dec 7–10, 2021.
Funding Information:
TS received honorarium from Roche and travel expenses for Gilead. SMR reports research funding from Pfizer/Conquer Cancer. JMP reports institutional research funding from Outcomes4me, serving as a consultant for Abbott Labs and spousal employment by GlaxoSmithKline. LS reports serving as an advisor to Blue Note Therapeutics and Rubedo Life Sciences and serving as a consultant for Novartis. VFB reports institutional research funding from SeaGen, AstraZeneca, Olema, and Oncosec, serving as a consultant for SeaGen and AstraZeneca, and serving as founder/stock ownership in PerlaTx. LAC reports institutional research funding from Syndax, Novartis, NanoString Technologies, SeaGen, VeraCyte, and AstraZeneca. EPW served over the past 3 years as a consultant to and received honoraria from Carrick Therapeutics, Genentech/Roche, and Jounce Therapeutics. He is an uncompensated member of the Scientific Advisory Boards for Leap Therapeutics. AHP reports royalties for co-authoring the Breast Cancer Survivorship section of UpToDate. The remaining authors declare no competing interests.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Extended adjuvant endocrine therapy (eET) improves outcomes in breast cancer survivors. Most studies however have been limited to postmenopausal women, and optimal eET for young survivors is uncertain. We report eET use among participants in the Young Women’s Breast Cancer Study (YWS), a multicenter prospective cohort of women age ≤40 newly diagnosed with breast cancer enrolled between 2006–2016. Women with stage I–III hormone receptor-positive breast cancer, ≥6 years from diagnosis without recurrence were considered eET candidates. Use of eET was elicited from annual surveys sent years 6–8 after diagnosis, censoring for recurrence/death. 663 women were identified as eET candidates with 73.9% (490/663) having surveys eligible for analysis. Among eligible participants, mean age was 35.5 (±3.9), 85.9% were non-Hispanic white, and 59.6% reported eET use. Tamoxifen monotherapy was the most reported eET (77.4%), followed by aromatase inhibitor (AI) monotherapy (21.9%), AI-ovarian function suppression (AI-OFS) (6.8%) and tamoxifen-OFS (3.1%). In multivariable analysis, increasing age (per year odds ratio [OR]: 1.10, 95% confidence interval [CI]: 1.04–1.16), stage (II v. I: OR: 2.86, 95% CI: 1.81–4.51; III v. I: OR: 3.73, 95%CI: 1.87–7.44) and receipt of chemotherapy (OR: 3.66, 95% CI: 2.16–6.21) were significantly associated with eET use. Many young breast cancer survivors receive eET despite limited data regarding utility in this population. While some factors associated with eET use reflect appropriate risk-based care, potential sociodemographic disparities in uptake warrants further investigation in more diverse populations.
AB - Extended adjuvant endocrine therapy (eET) improves outcomes in breast cancer survivors. Most studies however have been limited to postmenopausal women, and optimal eET for young survivors is uncertain. We report eET use among participants in the Young Women’s Breast Cancer Study (YWS), a multicenter prospective cohort of women age ≤40 newly diagnosed with breast cancer enrolled between 2006–2016. Women with stage I–III hormone receptor-positive breast cancer, ≥6 years from diagnosis without recurrence were considered eET candidates. Use of eET was elicited from annual surveys sent years 6–8 after diagnosis, censoring for recurrence/death. 663 women were identified as eET candidates with 73.9% (490/663) having surveys eligible for analysis. Among eligible participants, mean age was 35.5 (±3.9), 85.9% were non-Hispanic white, and 59.6% reported eET use. Tamoxifen monotherapy was the most reported eET (77.4%), followed by aromatase inhibitor (AI) monotherapy (21.9%), AI-ovarian function suppression (AI-OFS) (6.8%) and tamoxifen-OFS (3.1%). In multivariable analysis, increasing age (per year odds ratio [OR]: 1.10, 95% confidence interval [CI]: 1.04–1.16), stage (II v. I: OR: 2.86, 95% CI: 1.81–4.51; III v. I: OR: 3.73, 95%CI: 1.87–7.44) and receipt of chemotherapy (OR: 3.66, 95% CI: 2.16–6.21) were significantly associated with eET use. Many young breast cancer survivors receive eET despite limited data regarding utility in this population. While some factors associated with eET use reflect appropriate risk-based care, potential sociodemographic disparities in uptake warrants further investigation in more diverse populations.
UR - http://www.scopus.com/inward/record.url?scp=85154577676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85154577676&partnerID=8YFLogxK
U2 - 10.1038/s41523-023-00529-y
DO - 10.1038/s41523-023-00529-y
M3 - Article
AN - SCOPUS:85154577676
SN - 2374-4677
VL - 9
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 31
ER -